PMGC Holdings Inc. Announces Name Change of Wholly Owned Subsidiaries
PMGC Holdings Inc. (NASDAQ: ELAB) has announced the renaming of its wholly owned subsidiaries as part of a strategic realignment. Elevai Research Inc. has been renamed to PMGC Research Inc., which focuses on public-private collaborations leveraging research grants. Elevai Biosciences Inc. has been rebranded as Northstrive Biosciences Inc., a biopharmaceutical company targeting obesity with next-generation treatments. These changes reflect the company's evolution as a diversified holding company.
PMGC Holdings Inc. (NASDAQ: ELAB) ha annunciato la rinomina delle sue controllate al 100% come parte di un riallineamento strategico. Elevai Research Inc. è stata rinominata in PMGC Research Inc., che si concentra sulle collaborazioni tra pubblico e privato sfruttando i finanziamenti per la ricerca. Elevai Biosciences Inc. è stata rebranding come Northstrive Biosciences Inc., un'azienda biofarmaceutica che mira a combattere l'obesità con trattamenti di nuova generazione. Questi cambiamenti riflettono l'evoluzione della compagnia come un'azienda holding diversificata.
PMGC Holdings Inc. (NASDAQ: ELAB) ha anunciado el cambio de nombre de sus subsidiarias de propiedad total como parte de un reajuste estratégico. Elevai Research Inc. ha sido renombrada a PMGC Research Inc., que se centra en colaboraciones entre el sector público y privado aprovechando las subvenciones de investigación. Elevai Biosciences Inc. ha cambiado su marca a Northstrive Biosciences Inc., una empresa biofarma que se enfoca en la obesidad con tratamientos de nueva generación. Estos cambios reflejan la evolución de la empresa como una compañía holding diversificada.
PMGC Holdings Inc. (NASDAQ: ELAB)는 전략적 재조정의 일환으로 자회사 명칭을 변경한다고 발표했습니다. Elevai Research Inc.는 PMGC Research Inc.로 변경되었으며, 이는 연구 보조금을 활용한 공공-민간 협력에 중점을 둡니다. Elevai Biosciences Inc.는 비만을 대상으로 하는 차세대 치료제를 개발하는 생명공학 회사인 Northstrive Biosciences Inc.로 브랜드명이 변경되었습니다. 이러한 변화는 다각화된 지주회사로서의 회사의 진화를 반영합니다.
PMGC Holdings Inc. (NASDAQ: ELAB) a annoncé le changement de nom de ses filiales à 100 % dans le cadre d'un réalignement stratégique. Elevai Research Inc. a été renommée en PMGC Research Inc., qui se concentre sur les collaborations public-privé tirant parti des subventions de recherche. Elevai Biosciences Inc. a été rebrandée en Northstrive Biosciences Inc., une entreprise biopharmaceutique visant à lutter contre l'obésité avec des traitements de nouvelle génération. Ces changements reflètent l'évolution de la société en tant que société de portefeuille diversifiée.
PMGC Holdings Inc. (NASDAQ: ELAB) hat die Umbenennung seiner hundertprozentigen Tochtergesellschaften im Rahmen einer strategischen Neuausrichtung angekündigt. Elevai Research Inc. wurde in PMGC Research Inc. umbenannt, die sich auf öffentlich-private Kooperationen konzentriert, die Forschungsstipendien nutzen. Elevai Biosciences Inc. wurde als Northstrive Biosciences Inc. neu markiert, ein biopharmazeutisches Unternehmen, das sich mit modernen Behandlungen auf Fettleibigkeit spezialisiert. Diese Änderungen spiegeln die Entwicklung des Unternehmens als diversifiziertes Holdingunternehmen wider.
- None.
- None.
- PMGC Research Inc., formerly Elevai Research Inc., is a development company focused on public-private collaborations leveraging research grants.
- Northstrive Biosciences Inc., formerly Elevai Biosciences, Inc., is a biopharmaceutical company targeting obesity with next-generation treatments.
NEWPORT BEACH, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) is pleased to announce the renaming of its wholly owned subsidiaries as part of a strategic effort to better align with the company's evolving business focus as a diversified holding company. Effective immediately, the following name changes have taken place:
- Elevai Research Inc. is now PMGC Research Inc.
- Elevai Biosciences, Inc. is now Northstrive Biosciences Inc.
About PMGC Research Inc. (formerly Elevai Research Inc.)
PMGC Research Inc. is a research and development subsidiary of PMGC Holdings Inc. focused on advancing the frontiers of scientific discovery. Currently, the company is leveraging Canadian research grants and partnering with leading Canadian universities to push the boundaries of innovation in the biosciences field. Through strategic collaborations, PMGC Research Inc. is dedicated to transforming scientific breakthroughs into real-world solutions that improve health and well-being.
About Northstrive Biosciences Inc. (formerly Elevai Biosciences, Inc.)
Northstrive Biosciences Inc. is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22 is leveraging a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.
For more information, please visit www.northstrivebio.com.
Both PMGC Research Inc. and Northstrive Biosciences Inc. continue to focus on driving innovation and delivering transformative solutions in their respective fields.
For more information on PMGC Holdings Inc. and its subsidiaries, please visit www.pmgcholdings.com
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently, our portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC Holdings’ filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
IR@pmgcholdings.com
FAQ
What are the new names of PMGC Holdings' (ELAB) subsidiaries announced in January 2025?
What is the focus of PMGC Research Inc. (ELAB) after the 2025 rebranding?
What therapeutic area does Northstrive Biosciences (ELAB subsidiary) target?
Why did PMGC Holdings (ELAB) change its subsidiaries' names in 2025?
